Q4 2024 Absci Corp Earnings Call Transcript
Key Points
- Absci Corp (ABSI) successfully executed across all aspects of its business in 2024, including advancing proprietary internal programs and adding four new partners.
- The company unveiled its potentially category-defining ABS-201 program, targeting the prolactin receptor for androgenic alopecia, with promising pre-clinical data.
- Absci Corp's collaboration with AMD provides optimized compute solutions, enhancing performance and reducing costs for complex biological modeling.
- The company demonstrated significant advancements in its AI-integrated drug creation platform, showcasing breakthroughs in de novo antibody design.
- Absci Corp ended the year with a strong financial position, having raised an additional $40 million, extending its cash runway into the first half of 2027.
- Revenue for the fourth quarter was only $0.7 million, indicating limited financial growth from partnered programs.
- Research and development expenses increased significantly to $18.4 million, driven by internal program advancements and stock compensation expenses.
- The company plans to stop providing exact numbers of expected new partners, which may reduce transparency for investors.
- Absci Corp's cash, cash equivalents, and short-term investments decreased from $127.1 million to $112.4 million by the end of the year.
- The company faces competition in the androgenic alopecia market, with no real innovation in nearly 30 years, posing challenges for ABS-201's market entry.
Thank you for standing by. Welcome to Absci's fourth-quarter and full-year 2024 business update and financial operating results conference call.
(Operator Instructions) As a reminder, today's program is being recorded.
Now, I'd like to introduce your host for today's program, Alex Khan, Vice President of Finance and Investor Relations.
Thank you.
Earlier today, Absci released the financial and operating results for the quarter and year ended December 31, 2024. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an email to [email protected].
An archived webcast of this call will be available for replay at Absci's Investor Relations website, at investors.absci.com, for at least 90 days after this call.
Joining me, today, are Sean McLain, Absci's Founder and CEO; and Zach Jonasson, Chief Financial Officer and Chief Business Officer. Christian Stegmann, Absci's SVP of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
